Estrogen Receptor-Alpha and p53 Status as Regulators of AMPK and mTOR in Luminal Breast Cancer

SIMPLE SUMMARY: Endocrine therapy targeted against estrogen and the estrogen receptor is the main treatment modality for luminal breast cancer. Although a majority of patients respond to this treatment, one-third of all patients are resistant to this therapy. Hyperactive estrogen receptor along with...

Descripción completa

Detalles Bibliográficos
Autores principales: Gandhi, Nishant, Oturkar, Chetan C., Das, Gokul M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306694/
https://www.ncbi.nlm.nih.gov/pubmed/34298826
http://dx.doi.org/10.3390/cancers13143612

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306694/
https://www.ncbi.nlm.nih.gov/pubmed/34298826
http://dx.doi.org/10.3390/cancers13143612

Ejemplares similares